<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083342</url>
  </required_header>
  <id_info>
    <org_study_id>2009-12-087</org_study_id>
    <nct_id>NCT01083342</nct_id>
  </id_info>
  <brief_title>High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study</brief_title>
  <official_title>Open-labeled, Multicenter Phase II Study of High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the complete response (CR) rate after HD-MTX
      induction chemotherapy followed by alternative HD MTX-based and HD Cytarabine-based
      combination consolidation chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the complete response (CR) after chemotherapy</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the duration of response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the progression-free survival, overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety profiles</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">36</enrollment>
  <condition>CNS Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX, MVD, VIA</intervention_name>
    <description>MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Histologically confirmed Primary Central Nervous System (CNS) lymphoma

          2. Previously untreated. Patients treated with steroid alone are eligible.

          3. Performance status: ECOG 0-3.

          4. Age; 20-70

          5. Adequate renal function: Estimated glomerular filtration rate (GFR) or estimated
             creatinine clearance (CrCl) ≥ 50 mL/min

          6. Adequate liver functions: Transaminase (AST/ALT) &lt; 3 X upper normal value &amp; Bilirubin
             &lt; 2 X upper normal value

          7. Adequate hematological function: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥
             1,500/μL and platelet count ≥ 75,000/μL

          8. At least one cerebral mass lesion on magnetic resonance imaging (MRI) without
             involvement beyond the central nervous system (CNS)

          9. Life expectancy &gt; 6 months

         10. A negative serum or urine pregnancy test prior to treatment must be available both for
             pre menopausal women and for women who are &lt; 1 years after the onset of menopause.

         11. Informed consent

        Exclusion criteria

          1. Other subtypes NHL than Primary Central Nervous System (CNS) lymphoma

          2. Systemic involvement of Primary CNS lymphoma except leptomeningeal involvement

          3. Intraocular lymphoma

          4. HIV (+)

          5. Any other malignancies within the past 5 years except curatively treated non-melanoma
             skin cancer or in situ carcinoma of cervix uteri

          6. Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          7. Other serious illness or medical conditions

               -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months
                  prior to study entry

               -  History of significant neurological or psychiatric disorders

               -  Active uncontrolled infection (viral, bacterial or fungal infection)

          8. Patients who have HBV (+) are eligible. However, primary prophylaxis using antiviral
             agents (i.e. lamivudine) is recommended for HBV carrier to prevent HBV reactivation
             during whole treatment period.

          9. Concomitant administration of any other experimental drug under investigation, or
             concomitant chemotherapy, hormonal therapy, or immunotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WonSeog Kim, , M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Seog Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>primary CNS lymphoma</keyword>
  <keyword>MTX: Methotrexate,Leucovorin</keyword>
  <keyword>MVD: Methotrexate,Vincristine,Dexamethasone</keyword>
  <keyword>VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)</keyword>
  <keyword>Newly diagnosed primary CNS lymphoma patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

